Patents by Inventor Clara K. Miao

Clara K. Miao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating diseases and conditions associated with an altered level of amyloid ? peptides and new enolcarboxamide compounds
    Patent number: 7375220
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: May 20, 2008
    Assignees: Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Klaus Bornemann, Guenter Trummlitz, Edward S. Lazer, Clara K. Miao, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Ciossek, Marcus Kostka
  • 4-substituted beta-carbolines and analogs thereof
    Patent number: 6093723
    Abstract: This invention relates to 4-substituted .beta.-carbolines and .beta.-carboline analogs that inhibit Ca.sup.+2 influx and interleukin-2 (IL-2) production. The 4-substituted .beta.-carbolines and .beta.-carboline analogs of this invention are represented by formula (I): ##STR1## wherein Q, n, R, R', R" and R.sub.1 -R.sub.4 are as defined herein. This invention also relates to methods for producing .beta.-carbolines. Because of their selective immunomodulating properties, the compounds and pharmaceutical compositions of this invention are particularly well suited for preventing and treating immune disorders, including autoimmune disease, inflammatory disease, organ transplant rejection and other disorders associated with IL-2 mediated immune response.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 25, 2000
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Clara K Miao, Ian F. Potocki, Roger J. Snow, Karl D. Hargrave, Thomas P. Parks
  • Leukotriene biosynthesis inhibitors
    Patent number: 5552421
    Abstract: Various substituted benzoxazoles and benzothiazoles, are described and disclosed, which are potent inhibitors of leukotriene synthesis in warm-blooded animals.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 3, 1996
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Edward S. Lazer, Julian Adams, Clara K. Miao, Peter Farina
  • Leukotriene biosynthesis inhibitors
    Patent number: 5296486
    Abstract: Various substituted benzoxazoles, benzothiazoles, oxazolopyridines and thiazolopyridines are described and disclosed, compounds that are potent inhibitors of leukotriene synthesis in warm-blooded animals.
    Type: Grant
    Filed: September 4, 1992
    Date of Patent: March 22, 1994
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Edward S. Lazer, Julian Adams, Clara K. Miao, Peter Farina
  • Anti-inflammatory thienylbenzylamine compounds
    Patent number: 5030647
    Abstract: Novel thienylbenzylamine compounds of the formula ##STR1## wherein A and R.sub.1 -R.sub.5 are defined herein. These compounds are useful for the treatment of inflammation.
    Type: Grant
    Filed: February 9, 1990
    Date of Patent: July 9, 1991
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Clara K. Miao, Karl G. Grozinger, Robert Rothlein, Ronald Faanes, Genus Possanza, John P. Devlin